PMA Approval Process for Class III Devices

1. Key takeaways

Premarket Approval (PMA) is the primary market pathway for Class III devices, implemented under FD&C Act §515 and 21 CFR Part 814. FDA’s review time limits are 180 days (without an advisory panel) or 320 days (with an advisory panel). The PMA evidentiary standard is reasonable assurance of safety and effectiveness, and clinical data are generally required to support it.

• PMA and 510(k) operate on different evidentiary planes: PMA demands an absolute showing of reasonable assurance of safety and effectiveness, while 510(k) rests on comparison with a predicate.
• The 180-day and 320-day figures are FDA review clocks, not total project durations; IDE work, dossier preparation, clock stops for Additional Information requests, and panel scheduling all extend the real timeline.
• The FY2026 PMA/PDP/PMR/BLA fee is USD 579,272 (small business USD 144,818).
• First-time PMA applicants with total revenues below USD 30,000,000 may apply for a fee waiver under the MDUFA V small business provisions in 90 FR 35895.
• Approval is not the end: periodic reports are required after approval, and changes follow PMA supplements of different types with different fees.
• The four supplement categories carry different fees, so the category of each planned change should be identified before the change is implemented.

2. Legal basis

The table below sets out the statutory basis for PMA, the implementing regulation, the FY2026 fee schedule, and the official review time limits, each verified in 2026.

3. Expert insights

Insight 1: PMA and 510(k) do not operate on the same evidentiary plane. A 510(k) demonstrates substantial equivalence to a predicate device; a PMA demonstrates reasonable assurance of safety and effectiveness. The former is a comparative standard, while the latter involves an absolute judgment about safety and effectiveness, which is why clinical data, generated under an IDE in accordance with 21 CFR Part 812, are generally required for a PMA. Planning teams should never size a PMA program by analogy to a 510(k) program, because the depth and volume of evidence differ in kind, not merely in degree.

Insight 2: The 180-day figure is a review clock, and actual timelines are usually longer. The 180-day and 320-day limits are FDA review clocks. Scheduling must account for the IDE phase, dossier preparation time, clock interruptions caused by FDA requests for Additional Information, and possible advisory panel scheduling. In GRZAN’s PMA project planning, the 180-day figure is treated as the review segment only, never as the total project duration, and the surrounding segments are planned explicitly around it.

Insight 3: The PMA fee is more than twenty-two times the 510(k) fee. The FY2026 standard fees are USD 26,067 for a 510(k) and USD 579,272 for a PMA, with small business rates of USD 6,517 and USD 144,818 respectively. Companies filing a first PMA whose total revenues are below USD 30,000,000 may apply for a fee waiver under the MDUFA V small business provisions set out in 90 FR 35895. Fee planning should therefore include an early assessment of small business and waiver eligibility rather than a single standard-fee assumption.

Insight 4: Post-approval obligations continue after the PMA is granted. Approval is not the end of the process. Periodic reports must be submitted after approval, and changes to the approved device follow the PMA supplement route, divided by content into Panel-track, 180-day, Real-time, and 30-Day Notice categories, each with its own fee. Post-approval planning should be built into the original program so that changes are classified correctly at the time they are designed, not discovered afterward.

The practical consequence of these four points is that a PMA program is best managed as a multi-year portfolio rather than a single submission event. The clinical program, the dossier, the review segment, and the post-approval regime each have their own clocks, their own budgets, and their own failure modes. Organizations that assign a single owner across all four segments, with a plan that names the supplement category of every anticipated change, enter the market with fewer surprises and preserve the approval they worked so hard to obtain.

Internal briefing matters as much at the PMA stage as it did at the pathway-decision stage. Finance teams need to understand that the fee is only one line of a much larger program budget that includes the clinical phase. Engineering teams need to understand that a design change adopted casually can convert a routine update into a Panel-track supplement with its own cost and timeline. Aligning these audiences before the submission is filed is materially cheaper than re-educating them after the first supplement surprise.

4. Practical recommendations

• Structure the PMA project schedule around at least four segments: the IDE phase, dossier preparation, the review segment, and a buffer for Additional Information requests.
• Engage FDA on the clinical protocol during the IDE phase, so that completed data are not later found unusable for the application.
• Build the budget on the FY2026 fee of USD 579,272 (small business USD 144,818).
• Plan post-approval reporting and supplement routes in advance, so that a change does not turn out to require a Panel-track supplement only after it has been made.
• Complete small business qualification before the first submission; qualification does not apply retroactively to fees already paid.

5. Verification checklist

• □ Confirmed the device is Class III and requires a PMA.
• □ Determined whether an IDE and clinical data are required.
• □ Review segment scheduled at 180 days (or 320 days), with a buffer for Additional Information requests.
• □ Budget completed at the FY2026 rates.
• □ Small business qualification assessed, if applicable.
• □ Post-approval periodic reporting and supplement routes planned.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, US Agent and local testing support for the United States market. Our team manages FDA establishment registration and listing, 510(k)/De Novo/PMA submissions, and supports post-market reporting obligations. Business enquiries: info@grzanglobal.com